White Papers
Patient Access During Pre-Launch Phases
March 31, 2021
Why aren’t pharma teams shifting market access strategies to earlier phases of drug development? The influence of payers and PBMs is often poorly understood.
Why aren’t pharma teams shifting market access strategies to earlier phases of drug development? The influence of payers and PBMs is often poorly understood.
Description